Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $38.3 million.

  • Regenxbio's Accumulated Expenses fell 2122.86% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year decrease of 2122.86%. This contributed to the annual value of $38.1 million for FY2024, which is 2340.5% down from last year.
  • As of Q3 2025, Regenxbio's Accumulated Expenses stood at $38.3 million, which was down 2122.86% from $35.6 million recorded in Q2 2025.
  • Regenxbio's Accumulated Expenses' 5-year high stood at $76.1 million during Q4 2021, with a 5-year trough of $23.6 million in Q1 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $45.7 million (2023), whereas its average is $44.1 million.
  • In the last 5 years, Regenxbio's Accumulated Expenses soared by 10467.85% in 2021 and then plummeted by 3851.87% in 2022.
  • Regenxbio's Accumulated Expenses (Quarter) stood at $76.1 million in 2021, then plummeted by 38.52% to $46.8 million in 2022, then increased by 6.22% to $49.7 million in 2023, then decreased by 23.41% to $38.1 million in 2024, then grew by 0.65% to $38.3 million in 2025.
  • Its Accumulated Expenses was $38.3 million in Q3 2025, compared to $35.6 million in Q2 2025 and $23.6 million in Q1 2025.